Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?

Autor: Sylvain Lehmann, Christophe Hirtz, Shushil Choubey, Alberto Lleó, Mysore Sridhar Santosh, Constance Delaby, Bhavana Veerabhadrappa, Juan Fortea, Jérôme Vialaret, Daniel Alcolea

Publikováno v: Critical Reviews in Clinical Laboratory Sciences
Critical Reviews in Clinical Laboratory Sciences, Taylor & Francis, 2020, 57 (2), pp.99-113. ⟨10.1080/10408363.2019.1678011⟩

International audience; Alzheimer's disease (AD) is an incurable neurodegenerative disease characterized by progressive decline of cognitive abilities. Amyloid beta peptides (Aβ), Tau proteins and the phosphorylated form of the Tau protein, p-Tau, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0bd849bb150590ff527dcd039e8b95b
https://pubmed.ncbi.nlm.nih.gov/31661652